1. INTRODUCTION {#sec1}
===============

The average age of HIV-infected individuals has increased substantially in the past two decades. In 2016, there were 5.7 million people living with HIV (PLHIV) aged 50 years or older globally; 80% of which lived in low- and middle-income countries (LMICs) \[[@r1]\]. These numbers are projected to increase more than double in 2030 \[[@r2]\]. Prolonged life expectancy among HIV-1 infected individuals \[[@r3], [@r4]\] while reflects the success of antiretroviral therapy (ART) and access to treatment \[[@r5], [@r6]\] gives rise to a myriad of comorbidities associated with aging \[[@r7]-[@r12]\].

One particular concern for older PLHIVs is the increased risk of frailty, defined as a clinical state or a syndrome of increased vulnerability to physiological decline in response to stressors \[[@r13], [@r14]\]. Phenotypes of frailty were defined by Fried *et al.* using five criteria: unintentional weight loss, exhaustion, reduced physical activity, reduced walking speed, and weakening grip strength \[[@r15]\]. Frailty phenotypes are associated with increased fall incidence, disability, hospitalization, and death in the general population, while pre-frailty a reversible intermediary state between robust and frail is associated with the same outcomes, albeit less pronounced \[[@r15]-[@r19]\].

Frailty, among other geriatric syndromes, occurs at a younger age of about 10 years in HIV-1 infected individuals compared to the general population, and HIV is an independent risk factor for frailty \[[@r20]-[@r24]\]. Association between HIV-1 infection and frailty may be partly caused by changes in body composition, presenting as central obesity or lipodystrophy, provoked by HIV-1 pathogenesis itself or adverse effects of ART \[[@r25]-[@r29]\]. Other independent predictors of frailty among PLHIV were female sex and severe CD4+ cell depletion \[[@r30]-[@r32]\], and a persistent frailty phenotype predicted a worse prognosis after ART initiation \[[@r33], [@r34]\].

Similar to other LMICs, HIV-1 prevalence in Indonesia is still on the rise due to limited access to treatment 690,000 PLHIV (0.4%) were estimated in 2015, the largest in South-East Asia, and the population of PLHIV is aging \[[@r35]-[@r38]\]. Frailty is known to be more prevalent in LMICs \[[@r39], [@r40]\], while frailty prevalence among Indonesian general population in 2019 was 25.2% \[[@r41]\]; however, practically no data regarding frailty among PLHIV in Indonesia are available. In this study, we aimed to identify the prevalence of frailty and analyze associated factors, among HIV-1 infected adults under ART in Indonesia.

2. MATERIALS AND METHODS {#sec2}
========================

2.1. Study Sample and Data Collection {#sec2.1}
-------------------------------------

A cross-sectional study was conducted among HIV-1 infected patients aged 30 years or older, who underwent antiretroviral therapy for at least six months. Exclusion criteria were (1) currently treated for any opportunistic infections, (2) pregnancy, (3) disabilities which hinder physical examination *e.g.* paralysis or mentally ill, and (4) hospitalization within the last two months. Subject recruitment was conducted between September 2018 and January 2019 in HIV Integrated Service Unit of Cipto Mangunkusumo Hospital, Jakarta the national referral center for HIV cases in Indonesia. Questionnaires were administered in the first language of subjects, Bahasa Indonesia.

2.2. Frailty Criteria {#sec2.2}
---------------------

Identification of frailty phenotypes was based on five criteria as developed by Fried *et al.* \[[@r15]\]: (1) weight loss, (2) exhaustion, (3) low physical activity, (4) slowness, and (5) weakness (see **Appendix 1**).

*Weight loss* was defined by 4.5 kilograms loss in body weight in the last year or loss of \>5% body weight in the previous year. *Exhaustion* was measured using the two questions: "How often did you feel that every activity that you did are tiring?" and "How often did you feel that you could not do any activity due to your tiredness?" Response options were either none or rarely (\<1 day in a week), sometimes (1-2 days), often (3-4 days), or almost always (5-7 days). The criterion was met if subjects answered "often" or "almost always" to any one of the questions. *Low physical activity* was measured using the question, "Did you feel any physical limitation after having done any strenuous activities *e.g.* running or weight lifting?" Response options were either none at all, somewhat limited, or very limited; criterion was met if subjects answered the latter. *Slowness* was objectively measured by walking speed along 15-feet (4.57 m) distance, with average of two measurements was taken. Time of ≥7 s in men with a height of ≤173 cm, or ≥6 s in height of \>173 cm, or ≥7 s in women with a height of ≤159 cm, or ≥6 s in height of \>159 cm, were defined as slow. *Weakness* of grip strength was also objectively measured using Jamar Hydraulic Hand Dynamometer. Diagnosis of weakness was stratified based on gender and body mass index; in men: ≤29 kg grip strength in BMI ≤24 kg/m^2^, or ≤30 kg in 24.1-28 kg/m^2^, or ≤32 kg in \>28 kg/m^2^, while in women: ≤17 kg grip strength in BMI ≤23 kg/m^2^, or ≤17.3 kg in 23.1-26 kg/m^2^, or ≤18 kg in 26.1-29 kg/m^2^, or ≤21 kg in \>29 kg/m^2^.

Each criterion met was scored as one. Stages of frailty, as defined by Fried *et al.*, were then counted as follows: score of 0 means subject is *robust* or not frail, score of 1-2 means subject is at intermediate risk or considered to be *pre-frail*, and score of 3-5 means that subject is *frail*.

2.3. Independent Variables {#sec2.3}
--------------------------

To identify risk factors associated with frailty among PLHIV, several socio-demographic, medical history, as well as HIV-1-related variables were included in the analyses of this study: time since HIV-1 diagnosis, nadir CD4 count, BMI, presence of depression, presence and number of comorbidities, ART regiment, duration of ART, adherence, HIV-1 transmission risk factors, alcohol consumption, marital status, education, and family income. Comorbidities are defined as symptoms not related to acquired immunodeficiency syndrome (AIDS), or also known as non-AIDS defining illnesses; examples of which are diabetes mellitus and cardiovascular diseases. Presence of depression was assessed using the Beck's Depression Inventory-II (BDI-II) \[[@r42]\], which has been translated into Bahasa Indonesia (termed Indo BDI-II) and validated in the general population. Scores above the cut-off point of 17 indicate depression.

2.4. Statistical Analysis {#sec2.4}
-------------------------

Statistical analyses were performed using SPSS 16.0. Chi-square tests were performed for bivariate analyses of nominal variables with a 2-tailed p-value of \<0.05 was considered to be significant. Selected covariates were then included in multivariate analyses using logistic regression.

3. RESULTS {#sec3}
==========

3.1. Baseline Demographics {#sec3.1}
--------------------------

Of the 164 recruited subjects, 118 (72.0%) were male and the median age was 40.5 years old (Table **[1](#T1){ref-type="table"}**). Risk factors for HIV were mostly heterosexual transmission (53.7%) followed by injecting drug users (29.9%). Most subjects (75.6%) were clinically diagnosed for HIV more than five years ago, and most (72.6%) have been taking ART for more than five years as well. The most used regiment (70.1%) was non-nucleoside reverse transcriptase inhibitors (NNRTI)-based regiment, and most subjects (74.4%) reported good adherence to therapy, *i.e.* \>95% ART taken on schedule for the past three months. Most subjects (81.7%), however, had nadir CD4 count of \<200 cells/μl. Hepatitis C coinfection was the most common comorbidity, and 17.7% of subjects presented with 2 or more comorbidities. In terms of body composition, 28.7% of subjects presented with obesity or BMI ≥25kg/m^2^.

3.2. Prevalence and Characteristics of Frailty {#sec3.2}
----------------------------------------------

Frailty assessments were conducted on all subjects. Prevalence of pre-/frailty was 54.9%, of which most (51.2%) were classified into pre-frail and 3.7% were frail. The proportion of pre-/frailty increased in older age: 48.7% in subjects aged 30-39 years old, 57.6% in 40-49, and 66.7% in 50 or older (Fig. **[1](#F1){ref-type="fig"}**).

Weakness of grip strength was found in 71.1% of pre-/frailty subjects, which was markedly more common than exhaustion (23.3%), low physical activity (18.9%), weight loss (15.6%), and slow walking speed (6.7%).

3.3. Predictors of Frailty {#sec3.3}
--------------------------

Out of several risk factors analyzed in this study, as shown in Table **[2](#T2){ref-type="table"}**, bivariate analysis showed that depression was significantly associated with pre-/frailty (PR 1.36; 95% CI 1.03-4.44, *p*=0.038). Several covariates were continued into the multivariate model, shown in Table **[3](#T3){ref-type="table"}**, and it was found that depression also independently predicts the presence of pre-/frailty (OR 2.14; 95% CI 1.04-4.43, *p*=0.036). No other variables analyzed in this study, including age, nadir CD4 count, comorbidities, and BMI, were associated with frailty phenotype.

4. DISCUSSION {#sec4}
=============

4.1. Prevalence of Frailty and Associated Factors {#sec4.1}
-------------------------------------------------

Fried *et al.* introduced the frailty phenotype concept as aging comorbidity, where 7% of individuals over 65 years and as many as 26% over 80 years experienced frail \[[@r15]\]. The concept was adapted and applied in subsequent studies into HIV-1 infected population, in which frail was found in 5-19% of PLHIV in various age groups \[[@r21], [@r30], [@r31], [@r43]\].

In this study, criteria for frail were established in 3.7% of subjects and pre-frail in 51.2%. A study in South Africa recruited similar age groups as of our study \[[@r31]\], but the prevalence of frailty was found to be higher: 49.2% pre-frail and 19.4% frail. The same study, however, also recruited ART-naïve subjects that may skew clinical presentation of subjects. Other differences in demographics, *e.g.* higher proportion of women \[[@r30]\], may also explain the difference. Characteristic of censused PLHIV in Indonesia itself is leaning towards male in a 2:1 ratio \[[@r44]\], and the consecutive sampling nature of our study gives an output of more men included as subjects.

Pre-frail category as measured by Fried criteria represents intermediate-risk towards frail and associated negative outcomes, *e.g.* fall incidence and hospitalization. Frailty is known to occur earlier in PLHIV compared to the general population \[[@r21]-[@r23]\], and thus it is of benefit to recognize the pre-frail condition in PLHIV, even in younger age groups. [Fig. (**[1](#F1){ref-type="fig"}**)](#F1){ref-type="fig"} shows increased proportion of pre-frail as age increases, and more than half of 40-49 years old age group had at least one frailty phenotype. Similar results were shown by Kooij *et al.*, where proportion of pre-frail and frail showed upward trends as age increases, in both HIV positive and negative subjects \[[@r25]\].

Frailty, as defined by Fried, only considered the physical condition and does not take cognitive or psychological factors into account. Exclusion of both factors is a matter of debate, as they are well known as important contributors to geriatric disability; indeed, newer definition *e.g.* the frailty index (FI) by Rockwood included both domains \[[@r45], [@r46]\]. Depression the most frequent psychiatric disease including in PLHIV \[[@r47], [@r48]\] is 2-3 times higher in PLHIV than in the general population and has been implicated in decreased physical strength, work productivity, and social ability in aging individuals \[[@r49], [@r50]\]. In this study, depression was screened using the Indonesian version of Beck's Depression Inventory-II (BDI-II) \[[@r42]\]. Out of all subjects with depression, 68.2% of them belong to frailty group; multivariate analysis as shown in Table **[3](#T3){ref-type="table"}** also confirmed depression as an independent predictor of frailty. A study by Kooij *et al.* assessed for depression albeit with different instrument and found that 26.4% of subjects in the HIV positive group belonged to pre-frail and frail groups \[[@r25]\]. A study by Rees *et al.* also concluded that depression is strongly associated with frailty in HIV-infected patients \[[@r51]\]. These reports warrant further consideration into the impact of depression and psychological factors toward a physical condition in the aging population of PLHIV.

Our results also implicated that neurocognitive assessment linking to frailty in PLHIV is mandatory, as depression is closely associated with HIV-associated neurocognitive disorder (HAND) \[[@r52]-[@r54]\]. Indeed, cognitive impairment was found to be more common among frail (59%) compared to non-frail (34%) individuals, both of which predict poor outcomes \[[@r55], [@r56]\]. In Indonesia, the prevalence of HAND was 51% among treatment-naïve PLHIV but cognitive function improved and stabilized after 6 months of ART \[[@r57], [@r58]\]. Nevertheless, presence of dementia and cognitive function was not assessed in this study, which we acknowledge as an important limitation of the study.

Presence of comorbidity is closely related to the deteriorating physical condition of PLHIV and may become signs of progression towards frailty. In this study, the most common comorbidity found was hepatitis C. In line with a previous study by Önen *et al.*, hepatitis C was also identified as the most prevalent comorbidity, indicating that pro-inflammatory state caused by HIV-hepatitis C co-infection may clinically manifest as physical frailty \[[@r55]\]. Aging comorbidities *e.g.* metabolic and cardiovascular diseases, however, were not identified as predictors in this study, partly due to low incidence as younger age groups were recruited.

Several studies have identified low CD4 count as a strong independent predictor to frailty, and CD4 count of less than 100 cells/μl is correlated to slower gait and lower grip strength \[[@r21], [@r30]\]. In this study, most subjects had nadir CD4 count of less than 200 cells/μl, but no association to frailty were found. Similar results were also shown by Kooij *et al.* and Petit *et al.*, in which CD4 count (both nadir and current) showed no correlation to frailty phenotypes \[[@r25], [@r59]\]. In this study, we could only pick nadir CD4 for analysis, which is not enough to illustrate immune status of subjects and their progression. Laboratory monitoring for HIV is not covered by Indonesian national health insurance, so tests including CD4 are self-reliant, heavily limiting the frequency of CD4 measurements by PLHIV to once a year or less. A better way to represent immune progression might be the cumulative duration of CD4 \<200 which correlated to frailty in a study by Kooij *et al.* \[[@r25]\]; nevertheless, due to the lack of measurement in our subjects, our CD4 data is unreliable. Another point worth mentioning is that our analysis combined frailty and prefrailty as outcome; other studies with similar methodology \[[@r25], [@r59]\] showed non-association to CD4 status.

Earlier onset of frailty among PLHIV was considered to be related to pathologic changes in body composition, such as central obesity and lipodystrophy \[[@r26]\]. Our findings, however, showed no correlation between BMI and frailty outcomes. Alternatively, even though grip weakness and fatigue were the more dominant phenotypes in pre-frail group, frail group showed signs of weight loss and low physical activity, indicating that muscle wasting has occurred in frail condition. Muscle mass and presence of sarcopenia, however, were not assessed in this study, which left any link between frailty and muscle composition unexplored. Changes in fat and/or muscle composition may be caused by wasting syndrome associated with AIDS itself or adverse effect of ART, *e.g.* stavudine \[[@r29], [@r60]-[@r62]\]. Stavudine use, however, has been tapered off in Indonesia in the last decade due to toxicity \[[@r63], [@r64]\], and our analysis failed to show any association between ART regiment as a covariate to frailty phenotype.

Socioeconomic factors have been known to contribute to frailty, and frailty prevalence itself is higher in LMICs than in higher-income countries \[[@r39], [@r65]\], but the causal directionality remains unclear. Worsening of physical strength may lessen the ability to work and heighten risk of economic difficulties, which may lead to inability to pay for health insurance and poor nutritional intake, leading to frailty \[[@r39], [@r65]\]. This study, however, did not show any correlation between family income and frailty. Other similar studies also did not show any association between socioeconomic and education status to frailty \[[@r25], [@r55], [@r59]\] and it is likely that other unaccounted socioeconomic covariates such as economic balance and perception of financial well-being *i.e.* quality of life \[[@r66]-[@r68]\], plays a more important role.

4.2. Strength and Limitation {#sec4.2}
----------------------------

This study was the first to determine the proportion and associated factors of the pre-frail and frail condition in HIV-1 infected individuals in Indonesia. We also objectively measured frailty phenotypes instead of self-reporting methods that are prone to bias. In addition, we also identified the proportions of pre-frail and frail in younger age groups of PLHIV, many of whom experienced pre-frail and are at risk to progress further into frail phenotypes.

Cross-sectional study design, however, lacks the ability to establish any causal or temporal relationship between HIV-1-related risk factors and frailty, as well as frailty and associated outcomes, such as falls and disability. Being in a resource-limited setting, reliable datasets of CD4 count among other potential HIV-related risk factors, *e.g.* plasma viral load, were unavailable. Complete physical measurement, *e.g.* waist-hip circumference and bioelectrical impedance, may further elucidate the link between fat, muscle composition, and frailty.

Frailty phenotype as defined by Fried the most used measurement in frailty studies \[[@r69]\] only accounts for the physical condition of subjects, while neurocognitive and psychosocial aspects remain unassessed. Inclusion of BDI-II may help to indicate presence of depression, but thorough assessment of these two domains, preferably using the more comprehensive FI \[[@r45], [@r46]\], is warranted in frailty studies. An investigation into neurocognitive loss and HAND Inclusion of socioeconomic variables known to affect frailty *e.g.* quality of life \[[@r68], [@r70]\], may also shed further light into predictive factors of frailty among PLHIV.

CONCLUSION
==========

We identified frailty and associated risk factors among PLHIV under ART in Indonesia, of which frailty is a common occurrence. Depression was identified as an independent predictive factor to frailty, warranting further consideration into the mental health of aging PLHIV. It is imperative that longitudinal cohorts be conducted to further analyze frailty and predictive factors among PLHIV, particularly in LMICs.
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###### Criteria for frailty phenotype.

  --------------------------------------------------------------------------------------------------------------------------------------------------------------------
  **Criteria**            **Definition**
  ----------------------- --------------------------------------------------------------------------------------------------------------------------------------------
  Weight loss             \>10 pounds unintentional weight loss in last year or ≥5% of previous year's body weight

  Exhaustion              Subjects answering 2 or 3 to either one of two questions, "How often in the last week have you felt that:"\
                          Everything you did was an effort or\
                          You could not get going\
                          0 = rarely or none of the time (\<1 day)\
                          1 = some or a little of the time (1-2 days)\
                          2 = a moderate amount of the time (3-4 days)\
                          3 = most of the time

  Low physical activity   Subjects answering 3 to the questions, "Does your health limits your ability to do strenuous activities, e.g. running or weight lifting?"\
                          1 = not at all\
                          2 = somewhat limited\
                          3 = very limited

  Slow walking time       Stratified by gender and height:\
                          *Men; cut-off for time to walk 15 feet*\
                          Height ≤173 cm; ≥7 seconds\
                          Height \>173 cm; ≥6 seconds\
                          *Women; cut-off for time to walk 15 feet*\
                          Height ≤159 cm; ≥7 seconds\
                          Height \>159 cm; ≥6 seconds

  Weak grip strength      Stratified by gender and body mass index (BMI) quartiles:\
                          *Men; cut-off for grip strength*\
                          BMI ≤24; ≤29 kg\
                          BMI 24.1--26; ≤30 kg\
                          BMI 26.1--28; ≤30 kg\
                          BMI \>28; ≤32 kg\
                          *Women; cut-off for grip strength*\
                          BMI ≤23; ≤17 kg\
                          BMI 23.1--26; ≤17.3 kg\
                          BMI 26.1--29; ≤18 kg\
                          BMI \>29; ≤21 kg
  --------------------------------------------------------------------------------------------------------------------------------------------------------------------

###### Baseline characteristics.

  ------------------------------------------------------------------------------------------------------------------------------
  \-                                    **Total**\          **Robust**\   **Pre-frail (n = 84)**   **Frail**\    ***p* value**
                                        **(n = 164)**       **(n= 74)**                            **(n = 6)**   
  ------------------------------------- ------------------- ------------- ------------------------ ------------- ---------------
  **Gender, n(%)**                                                                                               

  Male                                  118 (72)            55 (46.6)     58 (49.2)                5 (4.2)       0.624

  **Age (years), n(%)**                                                                                          

  median (IQR)                          40.5 (36-47)        \-            \-                       \-            \-

  30 - 39                               78 (47.6)           40 (51.3)     34 (43.6)                4 (5.1)       0.309

  40 - 49                               59 (36)             25 (42.4)     33 (55.9)                1 (1.7)       \-

  50 - 59                               23 (14)             9 (39.1)      13 (56.5)                1 (4.3)       \-

  ≥ 60                                  4 (2.4)             0 (0)         4 (100)                  0 (0)         \-

  30 - \<50                             137 (83.5)          65 (47.4)     67 (48.9)                5 (3.6)       0.393

  ≥50                                   27 (16.5)           9 (33.3)      17 (63)                  1 (3.7)       \-

  **ART, n(%)**                                                                                                  

  NNRTI-based                           115 (70.1)          57 (49.6)     55 (47.8)                3 (2.6)       0.157

  PI-based                              49 (29.9)           17 (34.7)     29 (59.2)                3 (6.1)       \-

  **Marital status, n(%)**                                                                                       

  Married                               104 (63.4)          49 (47.1)     52 (50)                  3 (2.9)       0.908

  Single                                37 (22.6)           17 (45.9)     18 (48.6)                2 (5.4)       \-

  Separated                             6 (3.6)             2 (33.3)      4 (66.7)                 0 (0)         \-

  Widow                                 17 (10.4)           6 (35.3)      10 (58.8)                1 (5.9)       \-

  **Transmission risk factors. n(%)**                                                                            

  Heterosexual                          88 (53.7)           40 (44.7)     45 (51.1)                3 (3.4)       0.982

  Homosexual                            23 (14)             12 (52.2)     11 (47.8)                0 (0)         0.153

  Bisexual                              8 (4.9)             3 (37.5)      5 (62.5)                 0 (0)         0.732

  Piercing                              13 (7.9)            3 (23.1)      9 (69.2)                 1 (7.7)       0.281

  Injecting drug users                  49 (29.9)           22 (44.9)     23 (46.9)                4 (8.2)       0.127

  **Education, n(%)**                                                                                            

  Elementary or lower                   5 (3)               2 (40)        3 (60)                   0 (0)         0.049

  Junior high                           17 (10.4)           5 (29.4)      9 (52.9)                 3 (17.6)      \-

  High school                           91 (55.5)           41 (45.1)     47 (51.6)                3 (3.3)       \-

  University or higher                  51 (31.1)           26 (51)       25 (49)                  0 (0)         \-

  **Family income, n(%)**                                                                                        

  \<3.7 million rupiah                  82 (50)             34 (41.5)     44 (53.7)                4 (4.9)       0.567

  ≥3.7 million rupiah                   79 (48.2)           38 (48.1)     39 (49.4)                2 (2.5)       \-

  **Time to HIV-1 diagnosis, n(%)**                                                                              

  Median (IQR)                          7.6 (5 - 11.8)      \-            \-                       \-            \-

  ≥5 years                              124 (75.6)          55 (44.4)     64 (51.5)                5 (4)         0.871

  \<5 years                             40 (24.4)           19 (47.5)     20 (50)                  1 (2.5)       \-

  Median (IQR)                          7 (4.5-10.5)        \-            \-                       \-            \-

  ≥5 years                              119 (72.6)          52 (43.7)     62 (52.1)                5 (4.2)       0.737

  \<5 years                             45 (27.4)           22 (48.9)     22 (48.9)                1 (2.2)       \-

  **ART adherence, n(%)**                                                                                        

  Good                                  122 (74.4)          62 (50.8)     54 (44.3)                6 (4.9)       0.038

  History of non adherence              37 (22.6)           11 (29.7)     26 (70.3)                0 (0)         \-

  Non adherence                         5 (3)               1 (20)        4 (80)                   0 (0)         \-

  **Alcohol consumption, n(%)**                                                                                  

  Often                                 6 (3.6)             1 (16.7)      4 (66.6)                 1 (16.7)      0.157

  Rarely                                33 (20.1)           16 (48.5)     16 (48.5)                1 (3)         \-

  Never                                 125 (76.2)          57 (45.6)     64 (51.2)                4 (3.2)       \-

  **Comorbidities, n(%)**                                                                                        

  Diabetes                              17 (10.4)           7 (41.2)      10 (58.8)                0 (0)         0.615

  Hypertension                          16 (9.8)            8 (50)        7 (43.8)                 1 (6.2)       0.736

  Hepatitis B                           10 (6.1)            3 (30)        4 (40)                   3 (30)        0.000

  Hepatitis C                           39 (23.8)           15 (38.5)     21 (53.8)                3 (7.7)       0.241

  Lung disease                          35 (21.2)           12 (34.3)     20 (57.1)                3 (8.6)       0.111

  Others                                6 (3.6)             2 (33.3)      4 (66.7)                 0 (0)         0.701

  **Number of comorbidities, n(%)**                                                                              

  0-1 comorbidity                       135 (82.3)          64 (47.4)     68 (50.4)                3 (2.2)       0.071

  2 comorbidities or more               29 (17.7)           10 (34.5)     16 (55.2)                3 (10.3)      \-

  **Nadir CD4 count, n(%)**                                                                                      

  Median (IQR) cells/μl                 53 (21--147)        \-            \-                       \-            \-

  \<200 cells/μl                        134 (81.7)          60 (44.8)     69 (51.5)                5 (3.7)       0.980

  \>=200 cells/μl                       30 (18.3)           14 (46.7)     15 (50)                  1 (3.3)       \-

  **Body mass index, n(%)**                                                                                      

  Median (IQR) kg/m^2^                  22.8 (20.4--25.4)   \-            \-                       \-            \-

  \<25 kg/m^2^                          117 (71.3)          57 (48.7)     54 (46.2)                6 (5.1)       0.060

  ≥25 kg/m^2^                           47 (28.7)           17 (36.2)     30 (63.8)                0 (0)         \-

  **Depression, n(%)**                                                                                           

  No depression (BDI score \<17)        120 (73.2)          60 (50)       57 (47.5)                3 (2.5)       0.074

  Depression (BDI score ≥17)            44 (26.8)           14 (31.8)     27 (61.4)                3 (6.8)       \-
  ------------------------------------------------------------------------------------------------------------------------------

###### Bivariate analysis of factors associated to pre-/frailty phenotypes.

  **Variables**                    **Groups**   **Prevalence Ratio**   **95%CI**   ***p* value**   
  -------------------------------- ------------ ---------------------- ----------- --------------- -------
  ≥50                              18 (66.7)    9 (33.3)               1.26        0.76-4.29       0.178
  30 - \<50                        72 (52.6)    65 (47.4)              \-          \-              \-
  **Time to HIV-1 diagnosis**                                                                      
  ≥5 years                         69 (55.6)    55 (44.4)              1.05        0.56-2.32       0.728
  \<5 years                        21 (52.5)    19 (47.5)              \-          \-              \-
  **ART duration**                                                                                 
  ≥5 years                         67 (56.3)    52 (43.7)              1.10        0.62-2.45       0.551
  \<5 years                        23 (51.1)    22 (48.9)              \-          \-              \-
  **Nadir CD4 count**                                                                              
  \<200 cells/μl                   74 (55.2)    60 (44.8)              1.03        0.48-2.38       0.851
  ≥200 cells/μl                    16 (53.3)    14 (46.7)              \-          \-              \-
  **Comorbidities**                                                                                
  ≥2 comorbids                     19 (65.5)    10 (34.5)              1.25        0.74-3.95       0.204
  0-1 comorbid                     71 (52.6)    64 (47.4)              \-          \-              \-
  **BMI**                                                                                          
  ≥25 kg/m^2^                      30 (63.8)    17 (36.2)              1.24        0.84-3.37       0.144
  \<25 kg/m^2^                     60 (51.3)    57 (48.7)              \-          \-              \-
  ***Income***                                                                                     
  \<3.7 million rupiah             48 (58.5)    34 (41.5)              1.12        0.70-2.44       0.397
  ≥3.7 million rupiah              41 (51.9)    38 (48.1)              \-          \-              \-
  **Depression**                                                                                   
  Depression (BDI score ≥17)       30 (68.2)    14 (31.8)              1.36        1.03-4.44       0.038
  No depression (BDI score \<17)   60 (50)      60 (50)                \-          \-              \-

###### Multivariate analysis of factors associated to pre-/frailty phenotypes.

  **Variables**                    ***p\****   ***p*\*\***   **OR**     **95%CI\*\***
  -------------------------------- ----------- ------------- ---------- ----------------
  Age ≥50 years                    0.178       0.217         1.74       0.70-4.19
  ≥2 Comorbidities                 0.204       0.208         1.71       0.91-3.23
  BMI ≥25 kg/m^2^                  0.144       0.161         1.64       0.87-3.69
  **Depression (BDI score ≥17)**   **0.038**   **0.036**     **2.14**   **1.034-4.43**

\* in bivariate analysis, \*\* in multivariate analysis
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